TORONTO, May 16, 2022 (GLOBE NEWSWIRE) -- The RYAH Group Inc. leadership team is delighted to report that one of our lead developers, Maksym “Max” Rozdobudko (pictured below in an undisclosed location), is alive and well. RYAH continues to employ Max, with no change in terms, as he fights to preserve the freedom of his country.

Jordan Medley, Head of Product at RYAH, said “It had been 10 days since we last heard from Max, and of course, you can’t help worrying more and more about his safety with each day that passes. So when I received a message from him this week, and learned that he and his family are still safe, it brought about a personal sense of relief that’s almost impossible to describe. During his six years with RYAH, Max has been nothing short of exemplary in leading our front-end mobile app development, and his contributions have been essential to bringing our products to market. I continuously pray for his safety as he fights for his country.”

Sofiya Kleshchuk, Head of Client Relations at RYAH and a Ukrainian national living in New York, said “It is an unthinkable tragedy for all of our families and the whole nation. I am humbled by the commitment and dedication of Max and every Ukrainian defending Ukraine’s freedom today.”

Dr. Dave Richards and François Desrosiers, RYAH’s CEO and CFO, respectively, issued a joint statement saying “On behalf of RYAH’s Board and Leadership Team we wish to express our heartfelt appreciation and care for our Ukrainian colleagues, their friends and family, and the people of Ukraine. We strongly condemn Russia’s immoral military adventurism and war crimes.”

About RYAH Group Inc.

RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches, and pens. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping doctors and patients personalize treatments, control dosages, and better predict and monitor outcomes. The data and derived insights are also highly valuable for hospitals, clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers, and pharmaceutical companies, and to monitor and manage formulation effects on patients, based on dosages, strains, demographics, specific conditions, and a range of other factors. Exciting new directions under Dr. Richards’ leadership include R&D in the realm of blockchain, NFTs and cryptocurrency that will pave the way toward successful commercialization of RYAH’s big data assets. Through the above, a relentless focus on innovation, and track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio.